LifeMD, MD-Led Platform

LifeMD is a publicly traded (NASDAQ: LFMD) direct-to-patient telehealth company headquartered in New York that operates across all 50 states and covers weight management, men''s health (RexMD), hair loss, skincare, and primary care through a single integrated platform. The company''s weight management program launched as GLP-1 medications transformed the obesity treatment landscape, and LifeMD has since built its clinical infrastructure around making those medications accessible and affordable through strategic pharmaceutical partnerships. LifeMD is an authorized telehealth partner for Eli Lilly''s LillyDirect and Novo Nordisk''s NovoCare platforms. These partnerships give LifeMD patients access to manufacturer-direct pricing for Zepbound (tirzepatide) and Wegovy (semaglutide) — $349/month for Zepbound 2.5mg and $499/month for 5mg through the Lilly program — pricing tiers that bypass the standard retail pharmacy cost structure that makes brand-name GLP-1s unaffordable for uninsured patients. Wegovy is similarly available through NovoCare''s savings program, which LifeMD facilitates. The weight management program starts at $75/month on an annual plan and covers clinician consultations, lab evaluation, and care coordination. Medication costs are billed separately through insurance, manufacturer programs, or out-of-pocket. LifeMD is one of the few GLP-1 telehealth platforms that accepts traditional Medicare for clinical care, making it accessible to patients over 65 in most states — a population largely underserved by consumer-focused GLP-1 startups. RexMD, LifeMD''s men''s health arm, serves a complementary patient population and shares the same underlying provider network and platform infrastructure. Men managing weight alongside testosterone, sexual health, or hair loss concerns can access both programs through a single account. LifeMD does not offer compounded GLP-1 medications or a structured behavioral coaching curriculum comparable to Calibrate or Noom Med. The platform is best understood as a clinically credible, scalable telehealth company with strong pharmaceutical relationships — a meaningful option for patients who want brand-name GLP-1 access at reduced manufacturer pricing, or who want the reassurance of a publicly accountable company with national scale managing their care. The company''s weight management program launched as GLP-1 medications transformed the obesity treatment landscape, and LifeMD has since built its clinical infrastructure around making those medications accessible and affordable through strategic pharmaceutical partnerships. LifeMD is an authorized telehealth partner for Eli Lilly''s LillyDirect and Novo Nordisk''s NovoCare platforms. These partnerships give LifeMD patients access to manufacturer-direct pricing for Zepbound (tirzepatide) and Wegovy (semaglutide) — $349/month for Zepbound 2.5mg and $499/month for 5mg through the Lilly program — pricing tiers that bypass the standard retail pharmacy cost structure that makes brand-name GLP-1s unaffordable for uninsured patients. Wegovy is similarly available through NovoCare''s savings program, which LifeMD facilitates. The weight management program starts at $75/month on an annual plan and covers clinician consultations, lab evaluation, and care coordination. Medication costs are billed separately through insurance, manufacturer programs, or out-of-pocket. LifeMD is one of the few GLP-1 telehealth platforms that accepts traditional Medicare for clinical care, making it accessible to patients over 65 in most states — a population largely underserved by consumer-focused GLP-1 startups. RexMD, LifeMD''s men''s health arm, serves a complementary patient population and shares the same underlying provider network and platform infrastructure. Men managing weight alongside testosterone, sexual health, or hair loss concerns can access both programs through a single account. LifeMD does not offer compounded GLP-1 medications or a structured behavioral coaching curriculum comparable to Calibrate or Noom Med. The platform is best understood as a clinically credible, scalable telehealth company with strong pharmaceutical relationships — a meaningful option for patients who want brand-name GLP-1 access at reduced manufacturer pricing, or who want the reassurance of a publicly accountable company with national scale managing their care.